KR20190039951A - 췌장암의 치료를 위한 병용요법 - Google Patents

췌장암의 치료를 위한 병용요법 Download PDF

Info

Publication number
KR20190039951A
KR20190039951A KR1020197004431A KR20197004431A KR20190039951A KR 20190039951 A KR20190039951 A KR 20190039951A KR 1020197004431 A KR1020197004431 A KR 1020197004431A KR 20197004431 A KR20197004431 A KR 20197004431A KR 20190039951 A KR20190039951 A KR 20190039951A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
pancreatic cancer
inhibitor
mek inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197004431A
Other languages
English (en)
Korean (ko)
Inventor
제프 세틀맨
니세비타 사후
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20190039951A publication Critical patent/KR20190039951A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020197004431A 2016-08-23 2017-08-22 췌장암의 치료를 위한 병용요법 Ceased KR20190039951A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378322P 2016-08-23 2016-08-23
US62/378,322 2016-08-23
PCT/US2017/047985 WO2018039211A1 (en) 2016-08-23 2017-08-22 Combination therapy for the treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
KR20190039951A true KR20190039951A (ko) 2019-04-16

Family

ID=59762090

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197004431A Ceased KR20190039951A (ko) 2016-08-23 2017-08-22 췌장암의 치료를 위한 병용요법

Country Status (11)

Country Link
US (2) US10933058B2 (enExample)
EP (1) EP3503922B1 (enExample)
JP (2) JP7579636B2 (enExample)
KR (1) KR20190039951A (enExample)
CN (1) CN109641058A (enExample)
AU (1) AU2017316618A1 (enExample)
BR (1) BR112019002945A2 (enExample)
CA (1) CA3034259A1 (enExample)
IL (1) IL264589A (enExample)
MX (1) MX2019002121A (enExample)
WO (1) WO2018039211A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7579636B2 (ja) * 2016-08-23 2024-11-08 ジェネンテック， インコーポレイテッド 膵がん治療のための組み合わせ治療薬
WO2020014650A1 (en) * 2018-07-13 2020-01-16 Memorial Sloan Kettering Cancer Center Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer
CA3186465A1 (en) * 2019-10-22 2021-04-29 Chemistry Rx Methods for treating congenital epidermal hyperplasia
US20230112450A1 (en) * 2020-03-06 2023-04-13 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Combined use of ctb006 and ponatinib
CN115813930A (zh) * 2021-08-17 2023-03-21 赛诺哈勃药业（成都）有限公司 大环化合物与mek抑制剂联用在用于治疗疾病药物中的用途
CN116509852A (zh) * 2023-04-30 2023-08-01 兰州大学第二医院 含zinc218238819化合物的胰腺癌jak2和stat3双靶向抑制剂及应用
CN116585312A (zh) * 2023-04-30 2023-08-15 兰州大学第二医院 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EP3143166A4 (en) * 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
EP3256473A4 (en) * 2015-02-12 2018-08-01 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
JP7579636B2 (ja) * 2016-08-23 2024-11-08 ジェネンテック， インコーポレイテッド 膵がん治療のための組み合わせ治療薬

Also Published As

Publication number Publication date
JP7579636B2 (ja) 2024-11-08
EP3503922B1 (en) 2022-10-26
MX2019002121A (es) 2019-08-12
US10933058B2 (en) 2021-03-02
JP2019526559A (ja) 2019-09-19
AU2017316618A1 (en) 2019-02-07
BR112019002945A2 (pt) 2019-05-21
WO2018039211A1 (en) 2018-03-01
IL264589A (en) 2019-02-28
CA3034259A1 (en) 2018-03-01
JP2024170398A (ja) 2024-12-10
US20190175576A1 (en) 2019-06-13
CN109641058A (zh) 2019-04-16
EP3503922A1 (en) 2019-07-03
US20210283120A1 (en) 2021-09-16
US12419879B2 (en) 2025-09-23

Similar Documents

Publication Publication Date Title
US12419879B2 (en) Combination therapy for the treatment of pancreatic cancer
Herishanu et al. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications
Yan et al. Aurora‐A kinase: a potent oncogene and target for cancer therapy
Krytska et al. Crizotinib synergizes with chemotherapy in preclinical models of neuroblastoma
Saha et al. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa
Santiskulvong et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma
ES3033810T3 (en) Cancer treatments using combinations of cdk and erk inhibitors
AU2014368916B2 (en) Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors
CN107921050A (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
ES2992827T3 (en) Combination therapies targeting mitochondrial biogenesis for cancer therapy
US20140348819A1 (en) Methods of Treating Cancer
Dickerson et al. Imatinib and dasatinib inhibit hemangiosarcoma and implicate PDGFR-β and Src in tumor growth
Fahrenholtz et al. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts
Sahu et al. Cotargeting of MEK and PDGFR/STAT3 pathways to treat pancreatic ductal adenocarcinoma
Zhang et al. SEMA3C supports pancreatic cancer progression by regulating the autophagy process and tumor immune microenvironment
Langdon et al. Combinatorial screening of pancreatic adenocarcinoma reveals sensitivity to drug combinations including bromodomain inhibitor plus neddylation inhibitor
Zarrabi et al. Current and emerging therapeutic targets for metastatic renal cell carcinoma
Hoeflich et al. The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase
Saleh et al. Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
Pan et al. STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
HK40001148A (en) Combination therapy for the treatment of pancreatic cancer
US20240398814A1 (en) Kras inhibitor and hdac inhibitor combination for the treatment of cancer
El Sayed et al. Novel Combination Therapies for the Treatment of Solid Cancers
CN115025229A (zh) 一种igf1r调控肿瘤干性因子cd44的新应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190214

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200820

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221130

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230203

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221130

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I